Department of Ultrasound, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, Wenzhou, 325000, China.
Department of Chemoradiotherapy, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, Wenzhou, 325000, China.
World J Surg Oncol. 2020 Dec 4;18(1):318. doi: 10.1186/s12957-020-02077-2.
The proline-rich protein 11 (PRR11) is a newly identified oncogene associated with a poor prognosis in several human cancers. Nonetheless, research on its role in ovarian cancer (OC) remains largely understudied. Therefore, this study aims to evaluate the expression levels of PRR11 protein and its role in human ovarian cancer.
Immunohistochemistry analysis was used to evaluate the expression levels of PRR11 protein in human samples obtained from 49 patients diagnosed with OC and subjected to curative surgery in the First Affiliated Hospital of Wenzhou Medical University between 2007 and 2015.
In total, 57.1% of the primary OC tumor tissue evaluated demonstrated overexpression of PRR11. Meanwhile, the survival analysis showed that the overall survival (OS) of patients presenting overexpression of PRR11 was significantly lower than the OS of the patients with negative PRR11. In subsequent experiments, it was found that silencing the expression of PRR11 expression inhibited the proliferation of tumor cells and the migration of cells in vitro. Further, cells subjected to PRR11 knockdown exhibited a decrease in tumor growth in vivo. The downregulation of PRR11 was coupled with a decrease in N-cadherin and downregulation in the expression of early growth response protein 1 (EGR1).
The findings suggest that PRR11 might be considered as a potential target for prognostic assessment and gene therapy strategies for patients diagnosed with OC.
富含脯氨酸蛋白 11（PRR11）是一种新发现的癌基因，与多种人类癌症的不良预后相关。然而，其在卵巢癌（OC）中的作用研究仍很大程度上未被充分研究。因此，本研究旨在评估 PRR11 蛋白的表达水平及其在人类卵巢癌中的作用。
采用免疫组织化学分析方法，评估 2007 年至 2015 年期间在温州医科大学第一附属医院接受根治性手术治疗的 49 例 OC 患者的人组织样本中 PRR11 蛋白的表达水平。
在评估的原发性 OC 肿瘤组织中，有 57.1%表现出 PRR11 的过表达。同时，生存分析显示，PRR11 过表达患者的总生存期（OS）明显低于 PRR11 阴性患者的 OS。在随后的实验中，发现沉默 PRR11 的表达可抑制肿瘤细胞的增殖和体外细胞迁移。此外，PRR11 敲低的细胞在体内表现出肿瘤生长的减少。PRR11 的下调与 N-钙黏蛋白的减少和早期生长反应蛋白 1（EGR1）表达的下调有关。
这些发现表明，PRR11 可能被认为是 OC 患者预后评估和基因治疗策略的潜在靶点。
